A case of a digitate injection site reaction from subcutaneous bortezomib in a patient with myeloma
Abstract
The proteasome inhibitor bortezomib is widely used in the treatment of multiple myeloma. While peripheral neuropathy and gastrointestinal effects are well-documented adverse reactions to bortezomib administration, cutaneous side effects in patients with multiple myeloma are less commonly reported. We present a patient with IgG kappa multiple myeloma who developed a spider-like and digitate eruption at the site of subcutaneous bortezomib injection. This report expands the spectrum of bortezomib-associated dermatologic toxicity and emphasizes the importance of clinician awareness for prompt diagnosis and management.
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Ubiquitin and proteasome pathways
Cancer Treatment and Pharmacology
Publication details
- Journal / source
- SAGE Open Medical Case Reports
- Publisher
- SAGE Publications
- Volume
- 14
- Pages
- 2050313X251411508–2050313X251411508
- Publication date
- 1 January 2026
- Language
- EN